Clinical Characteristics and Survival in Patients with Brain Metastases From Pancreatic Cancer: A Retrospective Observational Study.

IF 2.5 4区 医学 Q3 ONCOLOGY
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-06-04 DOI:10.1177/10732748251347844
Susan Haag, Derek Cridebring
{"title":"Clinical Characteristics and Survival in Patients with Brain Metastases From Pancreatic Cancer: A Retrospective Observational Study.","authors":"Susan Haag, Derek Cridebring","doi":"10.1177/10732748251347844","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionBrain metastasis (BM) is an inauspicious finding in patients with pancreatic cancer, which significantly increases morbidity and mortality. The presentation is rare, and thus, outcomes on brain metastases from pancreatic cancer are limited.MethodsThis retrospective monocentric analysis included the electronic medical records of patients ≥ 18 years presenting with BM from pancreatic cancer. Clinical, demographic, and overall survival (OS) data were analyzed. Brain imaging (computed tomography, and magnetic resonance imaging) was used for BM diagnosis. OS was calculated from the date of diagnosis to either the date of last follow-up or death. Cox regression on OS time was used with an indicator variable for patients who ultimately developed a BM.ResultsBrain metastases was diagnosed in 34 (3.7%) patients with pancreatic cancer treated in our institution. Of the BM patients: 7 (22%) were non-White; 16 (47%) were female; the median age was 69; 35% were diagnosed at Stage II and III; and 65% were diagnosed at Stage IV. BM was the first diagnosed metastasis in 14 (41%) of the patients; in 5 individuals (15%) BM were detected within the first 100 days of pancreatic cancer diagnosis. OS from BM diagnosis was 9 months (95% CI [6.92,17.86]). The adjusted hazard ratio for patients with BM was .91(95% CI [.88, .94]; <i>P</i> = 0.60], which was not significant.ConclusionsDue to the low incidence of BM in pancreatic cancer, identification of disease remains a current challenge. In this study, we found that BM from pancreatic cancer may be the first sign that the cancer has spread. Using advanced neuroimaging early may help physicians diagnose these metastases sooner and possibly improve survival. With a larger cohort size, the findings may be potentially impactful for clinicians and patients. Prospective, multicentric studies are warranted to identify prognostic factors for treatment and survival.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347844"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138211/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10732748251347844","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

IntroductionBrain metastasis (BM) is an inauspicious finding in patients with pancreatic cancer, which significantly increases morbidity and mortality. The presentation is rare, and thus, outcomes on brain metastases from pancreatic cancer are limited.MethodsThis retrospective monocentric analysis included the electronic medical records of patients ≥ 18 years presenting with BM from pancreatic cancer. Clinical, demographic, and overall survival (OS) data were analyzed. Brain imaging (computed tomography, and magnetic resonance imaging) was used for BM diagnosis. OS was calculated from the date of diagnosis to either the date of last follow-up or death. Cox regression on OS time was used with an indicator variable for patients who ultimately developed a BM.ResultsBrain metastases was diagnosed in 34 (3.7%) patients with pancreatic cancer treated in our institution. Of the BM patients: 7 (22%) were non-White; 16 (47%) were female; the median age was 69; 35% were diagnosed at Stage II and III; and 65% were diagnosed at Stage IV. BM was the first diagnosed metastasis in 14 (41%) of the patients; in 5 individuals (15%) BM were detected within the first 100 days of pancreatic cancer diagnosis. OS from BM diagnosis was 9 months (95% CI [6.92,17.86]). The adjusted hazard ratio for patients with BM was .91(95% CI [.88, .94]; P = 0.60], which was not significant.ConclusionsDue to the low incidence of BM in pancreatic cancer, identification of disease remains a current challenge. In this study, we found that BM from pancreatic cancer may be the first sign that the cancer has spread. Using advanced neuroimaging early may help physicians diagnose these metastases sooner and possibly improve survival. With a larger cohort size, the findings may be potentially impactful for clinicians and patients. Prospective, multicentric studies are warranted to identify prognostic factors for treatment and survival.

胰腺癌脑转移患者的临床特征和生存率:一项回顾性观察研究。
脑转移(BM)在胰腺癌患者中是一个不吉利的发现,它会显著增加发病率和死亡率。这种表现是罕见的,因此,胰腺癌脑转移的结果是有限的。方法回顾性单中心分析纳入≥18岁的胰腺癌脑转移患者的电子病历。分析临床、人口统计学和总生存期(OS)数据。脑成像(计算机断层扫描和磁共振成像)用于脑转移诊断。总生存期从诊断日期计算至最后一次随访日期或死亡日期。对于最终发展为脑转移的患者,采用Cox回归和指标变量对OS时间进行分析。结果本院胰腺癌脑转移34例(3.7%)。BM患者中:非白种人7例(22%);16例(47%)为女性;中位年龄为69岁;35%诊断为II期和III期;65%的患者被诊断为IV期。14例(41%)患者首次诊断为转移瘤;5人(15%)在胰腺癌诊断的前100天内检测到BM。BM诊断后的OS为9个月(95% CI[6.92,17.86])。BM患者的校正危险比为0.91 (95% CI[。88年,总收入);P = 0.60],差异无统计学意义。结论由于BM在胰腺癌中的发病率较低,因此疾病的识别仍然是当前的一个挑战。在这项研究中,我们发现胰腺癌的骨髓转移可能是癌症扩散的第一个迹象。早期使用先进的神经影像学可以帮助医生更快地诊断这些转移,并可能提高生存率。随着队列规模的扩大,研究结果可能对临床医生和患者产生潜在影响。有必要进行前瞻性、多中心研究,以确定影响治疗和生存的预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Control
Cancer Control ONCOLOGY-
CiteScore
3.80
自引率
0.00%
发文量
148
审稿时长
>12 weeks
期刊介绍: Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信